Other languages Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
39.03 ^CNY	-0.89%		-0.96%	+11.48%

May. 27	Livzon Pharmaceutical Cancels 5.3 Million Share Options	MT
May. 14	Livzon Pharmaceutical Group Cancels Share Options	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Livzon Pharmaceutical Cancels 5.3 Million Share Options	May. 27
Livzon Pharmaceutical Group Cancels Share Options	May. 14
Livzon Pharmaceutical Declares Final Dividend for 2023	May. 13
Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	Apr. 26
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	Apr. 24
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	Mar. 29
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	Mar. 28
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	Feb. 23
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	Feb. 22
Livzon Pharma Gets Nod to Trial Weight Management Drug	Feb. 05
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President	Jan. 30
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	Jan. 18
Livzon Pharma Recognizes Credit, Asset Impairments	Jan. 10
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical	Jan. 02
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics	Dec. 18
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List	Dec. 14
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	Dec. 04
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use	Dec. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

Other languages

Filters